A new medical mandate is rolling out across the U.S. armed forces, and it has nothing to do with weapons training or combat drills. Starting soon, active-duty personnel age 30 and older will be required to have their testosterone levels checked every year.
Defense Secretary Pete Hegseth broke the news Wednesday in a video message shared on X, positioning the change as a routine addition to the physicals troops already undergo annually rather than a separate burden.
Younger service members under 30 can opt into testing but won’t be required to.
“I’m authorizing a new screening program for testosterone deficiency for our service members, ensuring you have the right testosterone levels to operate at your absolute best,” Hegseth said in the announcement.
Nobody will be forced onto medication as a result of the new checks. Hegseth was explicit that any treatment stemming from a diagnosis stays entirely up to the individual.
“If treatment is recommended, it’s entirely your choice to receive testosterone replacement therapy,” he said.
The defense chief pushed back on the notion that the program is designed to chemically enhance troops, casting it instead as preventive medicine.
“This initiative, it’s not about artificial enhancement,” Hegseth said. “It’s about restoring and optimizing your natural capabilities, protecting your longevity, ensuring you have the biological foundation required to sustain the fight.”
He tied the effort directly to combat performance, describing today’s warfighting environment as unforgiving.
“The modern battlefield is brutal and unrelenting,” he said. “It requires and demands maximum psychological and mental readiness, and by addressing these health markers early, we’re keeping you on the leading edge of lethality.”
Support for the rollout came quickly from HHS Assistant Secretary for Health Admiral Brian Christine, who praised the move in a post on X.
He wrote that balanced testosterone levels contribute to “strength, endurance, healthy body composition, cognitive performance, mission readiness, and overall well-being—ensuring America’s fighting force is prepared to perform at its highest level.”
Not everyone in Washington welcomed the announcement. Representative Pramila Jayapal argued the policy contradicts Hegseth’s own record, noting his prior restrictions on gender-related medical care in the ranks.
She wrote on X that providing hormone therapy to men with low testosterone “is gender-affirming care and it completely debunks all of Republicans’ attacks on trans people.”
Arizona Senator Mark Kelly also weighed in critically during a CNN interview, dismissing the initiative as misplaced priorities.
“It’s a weird idea,” Kelly said. “And what have we seen from this secretary of defense so far? We see him run around on a stage talking about lethality and killing people, now he’s talking about testosterone.”
Several logistical questions remain unanswered.
The Pentagon has not confirmed an exact start date for the screenings or said whether it will issue further clinical guidance. Officials have also stayed silent on whether women in uniform will be subject to the same testing.
Outside medical voices have raised doubts about how necessary widespread screening actually is.
Dr. Peter J. Snyder, who has overseen large NIH-backed testosterone studies in older men, told Newsweek that clinically low testosterone shows up in only about 2 percent of men, even near age 80, making blanket testing unusual by normal medical standards.
He said screening typically should be reserved for those already showing symptoms.
Snyder also flagged a practical hurdle: accurate testing calls for blood draws taken fasted, between 8 and 10 a.m., across three separate days.
He questioned how realistic that timeline is inside a military schedule, warning it raises the odds of false positives and unnecessary diagnoses.
When deficiency is genuinely confirmed, Snyder acknowledged the treatment can bring meaningful benefits, including gains in sexual function, mobility, mood and red blood cell counts.
He cautioned, however, that the therapy is not without danger, pointing to the TRAVERSE trial, a large placebo-controlled study of more than 5,200 men that linked treatment to risks like atrial fibrillation, blood clots in the lungs and bone fractures.
Testosterone itself governs several functions tied to physical readiness, including muscle mass, bone strength, red blood cell production and energy.
The Endocrine Society notes that deficiency can bring fatigue, weaker muscles, reduced stamina and mood disturbances, though the organization recommends treatment only after both testing and symptoms confirm a genuine shortfall.
Common delivery methods for replacement therapy include injections, topical gels, skin patches and implanted pellets.
Documented side effects range from acne and fluid buildup to reduced fertility, breast tissue growth and thickened blood that can raise clotting risk.
Women are treated differently under current medical standards.
Snyder stated flatly that “testosterone treatment is not approved for women under any circumstances,” noting that low levels in female patients are usually addressed instead through strength training, dietary changes and better sleep habits, since hormone therapy can trigger side effects like voice changes and unwanted hair growth.
The Pentagon’s move follows months of public commentary from HHS Secretary Robert F. Kennedy Jr. on male hormone health.
In an April 2025 Fox News interview, Kennedy claimed “a teenager today, an American teenager, has less testosterone than a 68-year-old man,” and stated that “testosterone levels have dropped 50 percent from historic levels.”
Kennedy has disclosed using his own physician-supervised testosterone regimen as part of an anti-aging plan.
Independent researchers have disputed portions of Kennedy’s framing, though they generally agree that average testosterone levels have trended downward over recent decades.
Scientists continue studying what combination of aging, lifestyle and environmental factors is driving that shift.
